export const ecdTestData = [
  {
    "id": "ecd-1",
    "sampleCategory": "Blood/Plasma",
    "name": "Shield",
    "vendor": "Guardant Health",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA screening (plasma)",
    "method": "NGS detecting cfDNA methylation patterns + fragmentomics + somatic mutations (~1Mb genome coverage)",
    "cancerTypes": [
      "Colorectal cancer (colon and rectal)"
    ],
    "targetPopulation": "Average-risk adults 45-84 years without prior CRC; adenomas; IBD; or hereditary CRC syndromes",
    "indicationGroup": "CRC",
    "sensitivity": 83.1,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "advancedAdenomaSensitivity": 13.2,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "advancedAdenomaSensitivityNotes": "Limited sensitivity for precancerous advanced adenomas (13.2%); blood-based tests generally less effective at detecting polyps than stool-based tests.",
    "stageISensitivity": 54.5,
    "stageIISensitivity": 100.0,
    "stageIIISensitivity": 96.0,
    "stageIVSensitivity": 87.5,
    "specificity": 89.6,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "ppv": 3.1,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "ppvDefinition": "PPV for colorectal cancer (CRC) in average-risk ECLIPSE screening population",
    "npv": 99.92,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "npvDefinition": "NPV for absence of CRC in average-risk ECLIPSE screening population",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "performanceNotes": "In ECLIPSE cfDNA blood test showed 83% sensitivity for CRC with 90% specificity. Stage I sensitivity 55-65%; limited detection of advanced adenomas (13.2%).",
    "leadTimeNotes": "No formal lead-time vs colonoscopy; positioned as guideline-accepted primary screening option every 3 years in average-risk adults",
    "fdaStatus": "FDA-approved PMA (P230009) July 26 2024 - First blood test for primary CRC screening; NCCN-recommended",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage per NCD 210.3; commercial coverage expanding",
    "commercialPayers": [],
    "commercialPayersCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Healths-Shield-Blood-Test-Now-Covered-for-VA-Community-Care-Beneficiaries/default.aspx",
    "commercialPayersNotes": "No commercial payer coverage yet. Government programs: VA Community Care Network covers Shield with no copay for average-risk individuals 45+; TRICARE also covers. Commercial insurance coverage pending USPSTF guideline inclusion and ACS recommendations. Once included in guidelines, expected to be covered under ACA preventive services.",
    "availableRegions": ["US"],
    "clinicalAvailability": "Commercially available in US since August 2024",
    "tat": "~14 days",
    "sampleType": "Whole blood in Guardant cfDNA BCT tubes",
    "sampleVolume": "4 tubes (minimum 2 mL plasma)",
    "sampleStability": "7 days at ambient temperature",
    "cptCode": "0537U",
    "codeType": "PLA",
    "medicareRate": 1495,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "listPrice": 895.0,
    "screeningInterval": "Every 3 years",
    "clinicalTrials": "NCT04136002 ECLIPSE CRC screening study (22877); NCT05716477 OSU Guardant Shield CRC Screening Project (300)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04136002 | https://clinicaltrials.gov/study/NCT05716477",
    "totalParticipants": 23177,
    "numPublications": 5,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-2",
    "sampleCategory": "Blood/Plasma",
    "name": "Galleri",
    "vendor": "GRAIL",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Tumor-naïve cfDNA methylation profiling with targeted NGS + machine-learning classifier; predicts cancer signal and tissue of origin (CSO)",
    "cancerTypes": [
      "50+ cancer types including colorectal, lung, pancreas, ovary, liver, head & neck, lymphoma, esophagus, stomach, bile duct, etc."
    ],
    "targetPopulation": "Asymptomatic adults ≥50 years as adjunct to standard single-cancer screening",
    "indicationGroup": "MCED",
    "sensitivity": 51.5,
    "sensitivityCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://pmc.ncbi.nlm.nih.gov/articles/PMC11024170/",
    "stageISensitivity": 16.8,
    "stageIISensitivity": 40.4,
    "stageIIISensitivity": 77.0,
    "stageIVSensitivity": 90.1,
    "specificity": 99.5,
    "specificityCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/",
    "ppv": 61.6,
    "ppvCitations": "https://www.galleri.com/hcp/galleri-test-performance",
    "ppvDefinition": "PPV for any cancer among participants with Cancer Signal Detected",
    "npv": 99.1,
    "npvCitations": "https://www.galleri.com/hcp/galleri-test-performance",
    "npvDefinition": "NPV for remaining cancer-free after No Cancer Signal Detected (12-month follow-up)",
    "tumorOriginAccuracy": 93,
    "tumorOriginAccuracyNotes": "Cancer Signal Origin (CSO) prediction accuracy: 93% top-1 prediction, 97% top-2 predictions in CCGA validation studies",
    "performanceCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://pmc.ncbi.nlm.nih.gov/articles/PMC11024170/ | https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/",
    "performanceNotes": "Overall cancer signal sensitivity ~51.5% with stage-specific sensitivity rising from ~17% at stage I to ~90% at stage IV; specificity ~99.5-99.6%.",
    "leadTimeNotes": "PATHFINDER and PATHFINDER 2 show ~7-fold increase in cancers detected when added to USPSTF A/B screening; median diagnostic resolution ~1.5 months",
    "fdaStatus": "LDT performed in CLIA-certified CAP-accredited lab; not FDA-approved; Breakthrough Device designation; PMA submission expected H1 2026",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Generally self-pay; most insurers and Medicare do not cover MCED as of 2025; TRICARE covers for ≥50 with elevated risk",
    "commercialPayers": ["Curative Insurance", "Fountain Health", "Alignment Health Plan"],
    "commercialPayersCitations": "https://grail.com/press-releases/curative-insurance-company-adds-grails-galleri-test-to-member-benefits-for-multi-cancer-early-detection/",
    "commercialPayersNotes": "Limited commercial coverage. Curative Insurance and Fountain Health offer $0 copay coverage. Alignment Health Plan (Medicare Advantage) covers in select CA/NC plans. Government programs: TRICARE covers with prior authorization for eligible beneficiaries ≥50. Most major commercial insurers consider investigational.",
    "availableRegions": ["US", "UK"],
    "clinicalAvailability": "Commercially available in US and some international markets as CLIA test since June 2021",
    "tat": "10-14 business days (up to 4 weeks during high volume)",
    "sampleType": "Whole blood in Streck cfDNA BCT tubes",
    "sampleVolume": "2 tubes",
    "sampleStability": "7 days at ambient temperature (1-40°C); do not refrigerate/freeze",
    "cptCode": "Proprietary",
    "listPrice": 949.0,
    "screeningInterval": "Annual recommended",
    "clinicalTrials": "NCT05611632 NHS-Galleri randomized screening trial (~140000); NCT05155605 PATHFINDER 2 safety/performance study (~35500); NCT03934866 SUMMIT high-risk lung cohort (13035)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05611632 | https://clinicaltrials.gov/study/NCT05155605 | https://clinicaltrials.gov/study/NCT03934866",
    "totalParticipants": 188535,
    "numPublications": 20,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-3",
    "sampleCategory": "Stool",
    "name": "Cologuard Plus",
    "vendor": "Exact Sciences",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool-based multitarget DNA test",
    "method": "Multitarget stool DNA assay with 5 novel methylation markers + hemoglobin immunoassay; streamlined from original 11 markers",
    "cancerTypes": [
      "Colorectal cancer; Advanced precancerous lesions (APL); High-grade dysplasia"
    ],
    "targetPopulation": "Average-risk adults 45-75 years for CRC screening at home",
    "indicationGroup": "CRC",
    "sensitivity": 93.9,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992 | https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2024/FDA-Approves-Exact-Sciences-Cologuard-Plus-Test-Setting-a-New-Benchmark-in-Non-Invasive-Colorectal-Cancer-Screening/default.aspx",
    "advancedAdenomaSensitivity": 43.4,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "advancedAdenomaSensitivityNotes": "43% sensitivity for advanced precancerous lesions (APL) including advanced adenomas and sessile serrated lesions ≥1cm; significantly outperforms FIT (23% for APL).",
    "stageISensitivity": 87.0,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIISensitivity": 94.0,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIIISensitivity": 97.0,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIVSensitivity": 100.0,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "specificity": 91.0,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992 | https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2024/FDA-Approves-Exact-Sciences-Cologuard-Plus-Test-Setting-a-New-Benchmark-in-Non-Invasive-Colorectal-Cancer-Screening/default.aspx",
    "ppv": 3.2,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "ppvDefinition": "PPV for colorectal cancer (CRC) in BLUE-C average-risk screening population",
    "npv": 99.98,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "npvDefinition": "NPV for absence of CRC in BLUE-C average-risk screening population",
    "performanceCitations": "BLUE-C pivotal trial NEJM 2024 (n=20000+); DeeP-C studies",
    "performanceNotes": "Pivotal data show 94% sensitivity for CRC and 43% for APL; significantly outperforms FIT (94% vs 67% for CRC; 43% vs 23% for APL).",
    "leadTimeNotes": "Non-invasive alternative to colonoscopy; 30% lower false positive rate vs original Cologuard; significantly improved adherence vs colonoscopy",
    "fdaStatus": "FDA-approved PMA October 4 2024",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage; $0 out-of-pocket for eligible; broad commercial payer coverage",
    "commercialPayers": ["Humana"],
    "commercialPayersCitations": "https://www.cologuard.com/insurance",
    "commercialPayersNotes": "Cologuard Plus confirmed coverage: Medicare Part B and Humana Medicare Advantage. Government programs: TRICARE expected based on legacy Cologuard coverage. Other major commercial payers (UnitedHealthcare, Aetna, Cigna, Anthem BCBS) anticipated to extend legacy Cologuard coverage to Plus but should be validated per plan.",
    "clinicalAvailability": "Commercially launched late March 2025 via ExactNexus (350+ health systems)",
    "tat": "3-5 days from receipt",
    "sampleType": "At-home stool collection with enhanced preservatives",
    "sampleVolume": "Stool sample",
    "sampleStability": "Extended return window vs original",
    "cptCode": "0464U",
    "listPrice": 790.0,
    "screeningInterval": "Every 3 years",
    "clinicalTrials": "NCT04144738 BLUE-C pivotal Cologuard Plus CRC screening trial (26758)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04144738",
    "totalParticipants": 26758,
    "numPublications": 2,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-4",
    "sampleCategory": "Stool",
    "name": "ColoSense",
    "vendor": "Geneoscopy",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool-based multitarget RNA test",
    "method": "8 stool-derived eukaryotic RNA (seRNA) transcripts via ddPCR + FIT - first FDA-approved RNA-based cancer screening test",
    "cancerTypes": [
      "Colorectal cancer; Advanced adenomas; Sessile serrated lesions"
    ],
    "targetPopulation": "Average-risk adults 45+ years for CRC screening",
    "indicationGroup": "CRC",
    "sensitivity": 93.0,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717 | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230001B.pdf",
    "stageISensitivity": 100.0,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "stageIISensitivity": 71.4,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "stageIIISensitivity": 100.0,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "specificity": 88.0,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717 | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230001B.pdf",
    "ppv": 1.9,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "ppvDefinition": "PPV for colorectal cancer (CRC) in PMA primary effectiveness cohort",
    "npv": 94.4,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "npvDefinition": "NPV for no advanced colorectal neoplasia (NAPL or negative colonoscopy)",
    "performanceCitations": "CRC-PREVENT JAMA 2023 (n=14263)",
    "performanceNotes": "CRC sensitivity 93-94% with 100% Stage I detection; advanced adenoma 45-46%; specificity 88%; outperforms FIT (94% vs 78% CRC; 46% vs 29% AA).",
    "leadTimeNotes": "Non-invasive RNA-based alternative; 100% Stage I sensitivity notable",
    "fdaStatus": "FDA-approved PMA May 3 2024; Breakthrough Device Designation January 2020",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Medicare coverage pending - NCD reconsideration requested; NCCN Guidelines included",
    "commercialPayers": [],
    "commercialPayersCitations": "",
    "commercialPayersNotes": "Emerging commercial and Medicaid coverage; no stable payer list yet. Medicare coverage pending NCD reconsideration.",
    "clinicalAvailability": "Launched via Labcorp partnership late 2024/early 2025",
    "tat": "Not publicly specified",
    "sampleType": "At-home stool collection (simplified kit FDA-approved 2025)",
    "sampleVolume": "Stool sample",
    "sampleStability": "Not specified",
    "cptCode": "0421U",
    "listPrice": 508.87,
    "screeningInterval": "Every 3 years (USPSTF)",
    "clinicalTrials": "NCT04739722 CRC-PREVENT pivotal ColoSense stool RNA CRC screening trial (14263)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04739722",
    "totalParticipants": 8920,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-5",
    "sampleCategory": "Blood/Plasma",
    "name": "Cancerguard",
    "vendor": "Exact Sciences",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based multi-biomarker MCED (plasma)",
    "method": "cfDNA methylation + tumor-associated proteins + DNA mutation reflex testing - first multi-biomarker class MCED",
    "cancerTypes": [
      "50+ cancer types (excludes breast and prostate); 6 deadliest cancers: pancreatic, lung, liver, esophageal, stomach, ovarian"
    ],
    "targetPopulation": "Adults 50-84 years with no cancer diagnosis in past 3 years",
    "indicationGroup": "MCED",
    "sensitivity": 64.0,
    "sensitivityCitations": "https://www.exactsciences.com/cancer-testing/cancerguard-mced-providers/resources",
    "specificity": 97.4,
    "specificityCitations": "https://www.exactsciences.com/cancer-testing/cancerguard-mced-providers/resources",
    "ppv": 19.4,
    "ppvDefinition": "PPV for any cancer in DETECT-A CancerSEEK interventional study",
    "npv": 99.3,
    "npvDefinition": "NPV for absence of any cancer in DETECT-A CancerSEEK interventional study",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Does not predict tissue of origin; uses imaging-guided diagnostic resolution pathway instead (up to $6,000 covered imaging workup)",
    "performanceCitations": "DETECT-A (n=10006); ASCEND-2 (n=6354); FALCON Registry (n=25000 ongoing)",
    "performanceNotes": "64% sensitivity for 17 cancer types excluding breast/prostate; 68% for 6 deadliest cancers; >33% early-stage (I-II) detected; 97.4% specificity.",
    "leadTimeNotes": "First-of-its-kind multi-biomarker approach; imaging-guided resolution (no tissue of origin prediction)",
    "fdaStatus": "LDT; not FDA-approved; Breakthrough Device Designation (via CancerSEEK)",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not covered by Medicare or commercial payers; not billed to insurance; FSA/HSA eligible",
    "clinicalAvailability": "Launched September 2025 via Quest Diagnostics (7000+ sites)",
    "availableRegions": ["US"],
    "tat": "Not publicly specified",
    "sampleType": "Whole blood in LBgard tubes",
    "sampleVolume": "4 tubes × 8.5 mL = 34 mL total",
    "sampleStability": "72 hours at room temperature (15-25°C)",
    "cptCode": "Proprietary",
    "listPrice": 689.0,
    "screeningInterval": "Annual recommended",
    "clinicalTrials": "DETECT-A prospective interventional MCED (10006); ASCEND-2 classifier development (6354); NCT06589310 FALCON Registry (25000 target)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06589310",
    "totalParticipants": 16360,
    "numPublications": 2,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-6",
    "sampleCategory": "Blood/Plasma",
    "name": "Freenome CRC Blood Test",
    "vendor": "Freenome",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA multiomics (plasma)",
    "method": "AI/ML analyzing genomic + epigenomic (single-base methylation) + proteomic biomarkers",
    "cancerTypes": [
      "Colorectal cancer; Advanced adenomas"
    ],
    "targetPopulation": "Average-risk adults for CRC screening",
    "indicationGroup": "CRC",
    "sensitivity": 79.2,
    "sensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer | https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.18",
    "stageISensitivity": 57.1,
    "stageISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIISensitivity": 100.0,
    "stageIISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIIISensitivity": 82.4,
    "stageIIISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIVSensitivity": 100.0,
    "stageIVSensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "specificity": 91.5,
    "specificityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer | https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.18",
    "ppvDefinition": "PPV for advanced colorectal neoplasia in PREEMPT CRC (not yet populated)",
    "npvDefinition": "NPV for advanced colorectal neoplasia in PREEMPT CRC (not yet populated)",
    "performanceCitations": "PREEMPT CRC JAMA June 2025 (n=48995 enrolled; 27010 analyzed)",
    "performanceNotes": "79.2% CRC sensitivity with 57.1% Stage I; 12.5% advanced adenoma (29% for high-grade dysplasia); 91.5% specificity.",
    "leadTimeNotes": "Largest blood-based CRC screening study (PREEMPT CRC n=48995); multiomics approach combines multiple biomarker classes",
    "fdaStatus": "PMA application submitted (final module August 2025); Exact Sciences exclusive US licensing agreement announced August 2025",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not yet established",
    "clinicalAvailability": "Not yet commercially available - pending FDA approval",
    "tat": "Not applicable - not yet available",
    "sampleType": "Blood",
    "sampleVolume": "Not specified",
    "sampleStability": "Not specified",
    "cptCode": "UNKNOWN",
    "screeningInterval": "Expected every 3 years",
    "clinicalTrials": "NCT04369053 PREEMPT CRC registrational Freenome blood-based CRC screening study (48995 enrolled; 27010 analyzed)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04369053",
    "totalParticipants": 48995,
    "numPublications": 2,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-7",
    "sampleCategory": "Blood/Plasma",
    "name": "FirstLook Lung",
    "vendor": "DELFI Diagnostics",
    "testScope": "Single-cancer (Lung)",
    "approach": "Blood-based cfDNA fragmentomics",
    "method": "Low-pass whole genome sequencing analyzing cfDNA fragment length patterns + ML classifier - detects chaotic DNA packaging from cancer cells",
    "cancerTypes": [
      "Lung cancer (screening enhancement - pre-LDCT risk stratification)"
    ],
    "targetPopulation": "USPSTF-eligible: Adults 50-80 years; ≥20 pack-years smoking history; current smokers or quit within 15 years",
    "indicationGroup": "Lung",
    "sensitivity": 80.0,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageISensitivity": 71.0,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIISensitivity": 89.0,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIIISensitivity": 88.0,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIVSensitivity": 98.0,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "specificity": 58.0,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "ppvDefinition": "PPV for lung cancer among Elevated results in high-risk USPSTF screening population",
    "npv": 99.7,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "npvDefinition": "NPV for being lung-cancer free among Not Elevated results in high-risk USPSTF screening population",
    "performanceCitations": "DELFI-L101 Cancer Discovery 2024 (n=958); CASCADE-LUNG/L201 (NCT05306288); FIRSTLung/L301 (NCT06145750)",
    "performanceNotes": "80% overall sensitivity (71% Stage I; 98% Stage IV); 58% specificity; 99.7% NPV; fragmentomics approach novel mechanism.",
    "leadTimeNotes": "Pre-LDCT risk stratification; 5.5× higher cancer likelihood with Elevated result; designed to increase LDCT uptake (currently only 6% eligible adults screened)",
    "fdaStatus": "LDT; FDA IVD submission planned",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not established; not covered by Medicare",
    "clinicalAvailability": "Early Experience Program at select health systems (OSF HealthCare; City of Hope; Indigenous Pact)",
    "tat": "10-14 business days",
    "sampleType": "Standard blood draw",
    "sampleVolume": "<1 mL plasma required",
    "sampleStability": "Standard",
    "cptCode": "UNKNOWN",
    "listPrice": 300.0,
    "screeningInterval": "Annual (complement to LDCT)",
    "clinicalTrials": "NCT05306288 CASCADE-LUNG prospective validation (15000 target); NCT04825834 DELFI-L101 case-control development (958); NCT06145750 FIRSTLung cluster RCT (ongoing)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05306288 | https://clinicaltrials.gov/study/NCT04825834 | https://clinicaltrials.gov/study/NCT06145750",
    "totalParticipants": 15958,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-8",
    "sampleCategory": "Blood/Plasma",
    "name": "HelioLiver",
    "vendor": "Helio Genomics",
    "testScope": "Single-cancer (HCC/Liver)",
    "approach": "Blood-based cfDNA methylation + protein biomarkers",
    "method": "AI algorithm analyzing cfDNA methylation patterns + AFP + AFP-L3 + DCP + demographics",
    "cancerTypes": [
      "Hepatocellular carcinoma (HCC)"
    ],
    "targetPopulation": "Adults with cirrhosis; chronic HBV carriers; high-risk for HCC",
    "indicationGroup": "Liver",
    "sensitivity": 85.0,
    "sensitivityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",
    "stageISensitivity": 76.0,
    "stageISensitivityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",
    "specificity": 91.0,
    "specificityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9234637/",
    "ppvDefinition": "PPV for hepatocellular carcinoma (HCC) in high-risk surveillance population (cirrhosis / chronic HBV)",
    "npvDefinition": "NPV for absence of HCC in high-risk surveillance population (cirrhosis / chronic HBV)",
    "performanceCitations": "ENCORE Hepatology Communications 2022 (n=247); CLiMB EASL 2024 (n=1968); VICTORY (n=1100)",
    "performanceNotes": "85% overall sensitivity with 76% early-stage; 91% specificity; AUC 0.944 vs AFP 0.851 and GALAD 0.899.",
    "leadTimeNotes": "Significantly outperforms ultrasound for early-stage HCC detection (44.4% vs 11.1% for T1 tumors); designed as surveillance tool",
    "fdaStatus": "PMA submitted Q2 2024 (Class III); currently LDT",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Expected upon FDA approval; CPT code 0333U assigned",
    "clinicalAvailability": "Commercially available as LDT",
    "tat": "Not publicly specified",
    "sampleType": "Blood (serum for proteins; plasma for cfDNA)",
    "sampleVolume": "Standard blood draw",
    "sampleStability": "Standard",
    "cptCode": "0333U",
    "screeningInterval": "Every 6 months (per AASLD)",
    "clinicalTrials": "NCT05059665 ENCORE validation (247); NCT03694600 CLiMB prospective HCC surveillance (1968); VICTORY study (1100)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05059665 | https://clinicaltrials.gov/study/NCT03694600",
    "totalParticipants": 3315,
    "numPublications": 2,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-9",
    "sampleCategory": "Blood/Plasma",
    "name": "Oncoguard Liver",
    "vendor": "Exact Sciences",
    "testScope": "Single-cancer (HCC/Liver)",
    "approach": "Blood-based methylated DNA markers + protein",
    "method": "3 methylated DNA markers (HOXA1; EMX1; TSPYL5) + AFP + biological sex; LQAS PCR technology; developed with Mayo Clinic",
    "cancerTypes": [
      "Hepatocellular carcinoma (HCC)"
    ],
    "targetPopulation": "Adults with cirrhosis; chronic HBV; high-risk for HCC requiring surveillance",
    "indicationGroup": "Liver",
    "sensitivity": 88.0,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34419598/",
    "stageISensitivity": 82.0,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34419598/",
    "specificity": 87.0,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/34419598/",
    "ppvDefinition": "PPV for HCC in high-risk surveillance population (ALTUS / validation cohorts)",
    "npvDefinition": "NPV for absence of HCC in high-risk surveillance population (ALTUS / validation cohorts)",
    "performanceCitations": "Phase II validation CGH 2021; ALTUS NCT05064553 (n>3000) November 2025",
    "performanceNotes": "88% overall sensitivity; 82% early-stage (BCLC 0/A); 87% specificity; AUC 0.91 vs AFP 0.84 and GALAD 0.88.",
    "leadTimeNotes": "ALTUS study shows 77% early-stage vs 36% for ultrasound; 64% very early-stage vs 9% for ultrasound (6-7× improvement)",
    "fdaStatus": "LDT; Breakthrough Device Designation October 2019",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "NOT covered by Medicare; financial assistance available (1-844-870-8870)",
    "clinicalAvailability": "Commercially available",
    "tat": "~1 week",
    "sampleType": "Blood (Exact Sciences collection kit)",
    "sampleVolume": "Standard blood draw",
    "sampleStability": "Standard",
    "cptCode": "81599",
    "screeningInterval": "Every 3-6 months",
    "clinicalTrials": "NCT05064553 ALTUS prospective HCC surveillance (3000+); Phase II validation CGH 2021",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05064553",
    "totalParticipants": 3000,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-10",
    "sampleCategory": "Blood/Plasma",
    "name": "Shield MCD",
    "vendor": "Guardant Health",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Methylation-based NGS cfDNA platform detecting 10 cancer types; same Shield platform as CRC test with expanded analysis; requires physician opt-in and patient authorization for EMR data release",
    "cancerTypes": [
      "Bladder; Colorectal; Esophageal; Gastric; Liver; Lung; Ovarian; Pancreas; Breast; Prostate (10 tumor types)"
    ],
    "targetPopulation": "Average-risk adults 45+ years; ordered as add-on when physician requests Shield CRC test",
    "indicationGroup": "MCED",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Cancer signal of origin prediction included; specific accuracy not yet publicly disclosed; performance data presented at AACR/ASCO 2025",
    "sensitivity": 60.0,
    "sensitivityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Presents-Data-Demonstrating-Strong-Performance-of-Shield-Multi-Cancer-Detection-Test-Across-10-Tumor-Types/default.aspx",
    "sensitivityNotes": "Overall episode-based sensitivity ~60% across all 10 cancer types; ~74% sensitivity for subset of deadliest/aggressive cancers. Data from interim MCED performance presented at AACR/ASCO 2025.",
    "sensitivityType": "episode-based interim",
    "specificity": 98.5,
    "specificityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Presents-Data-Demonstrating-Strong-Performance-of-Shield-Multi-Cancer-Detection-Test-Across-10-Tumor-Types/default.aspx",
    "specificityNotes": "~98.5% specificity from interim Shield MCED data. High specificity critical for screening use to minimize false positives.",
    "ppvDefinition": "PPV for any of 10 target cancers among positive Shield MCD results (not yet reported)",
    "npvDefinition": "NPV for remaining cancer-free among negative Shield MCD results (not yet reported)",
    "performanceCitations": "AACR 2025 oral presentation; ASCO 2025; NCI Vanguard Study (NCT pending; n=24000); Guardant Health Investor Relations 2025",
    "performanceNotes": "Overall sensitivity ~60% across all cancers; ~74% sensitivity for subset of deadliest cancers; ~98.5% specificity. Performance data from interim MCED analysis supported NCI selection for Vanguard Study.",
    "leadTimeNotes": "Available as add-on to Shield CRC screening; physician must opt-in and patient must authorize release of medical records to Guardant in exchange for MCD results",
    "fdaStatus": "LDT; FDA Breakthrough Device Designation (June 2025); selected for NCI Vanguard Study (24000 participants); Shield MCD reviewed by FDA as part of NCI investigational device exemption (IDE)",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not covered by Medicare or commercial payers; no additional cost when ordered with Shield CRC (data exchange model)",
    "clinicalAvailability": "Launched nationally October 2025; available when ordering Shield CRC test with physician opt-in",
    "availableRegions": ["US"],
    "tat": "~14 days (same blood draw as Shield CRC)",
    "sampleType": "Whole blood in Guardant cfDNA BCT tubes (same sample as Shield CRC)",
    "sampleVolume": "4 tubes (no additional blood draw required)",
    "sampleStability": "7 days at ambient temperature",
    "cptCode": "UNKNOWN",
    "screeningInterval": "Annual recommended (with Shield CRC every 3 years)",
    "clinicalTrials": "NCI Vanguard Study multi-cancer detection feasibility (24000 target); AACR 2025 presentations; ASCO 2025 presentations",
    "totalParticipants": 24000,
    "numPublications": 0
  },
  {
    "id": "ecd-11",
    "sampleCategory": "Blood/Plasma",
    "name": "EPISEEK",
    "vendor": "Precision Epigenomics",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Methylation-specific PCR detecting hypermethylated cfDNA loci across 60+ cancer types including all 20 most fatal cancers; does not use NGS; analyzes 10 cancer biomarkers",
    "cancerTypes": [
      "60+ cancer types including all 20 most fatal cancers: lung, liver, pancreas, esophageal, bladder, stomach, head & neck SCC, uterine, low-grade glioma, high-grade glioma (brain cancer detection believed unique among blood-based MCED tests)"
    ],
    "targetPopulation": "Adults 45+ years with elevated cancer risk; can be considered from age 21 with risk factors (smoking, family history)",
    "indicationGroup": "MCED",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Does not predict tissue of origin (no CSO/TOO); requires standard diagnostic workup to localize cancer source",
    "sensitivity": 54.0,
    "sensitivityCitations": "https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3144 | https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "sensitivityNotes": "Overall incidence-adjusted sensitivity (IAS) across all stages. IAS is more conservative than observed sensitivity as it weights by cancer incidence.",
    "stageISensitivity": 45.0,
    "stageISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageIISensitivity": 45.0,
    "stageIISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageISensitivityNotes": "Combined Stage I/II IAS = 45%. For aggressive unscreened cancers (bladder, esophagus, liver, H&N, lung, pancreas, stomach, uterine) Stage I/II sensitivity is 57%.",
    "stageIIISensitivity": 73.0,
    "stageIIISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageIVSensitivity": 74.0,
    "stageIVSensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "specificity": 99.5,
    "specificityCitations": "https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3144 | https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "ppv": 64.9,
    "ppvDefinition": "PPV in validation cohort (n=482). Modeled PPV of 40% in screening population age 50+.",
    "npv": 99.5,
    "npvDefinition": "NPV for absence of cancer in validation cohort",
    "performanceCitations": "Pham TH et al. J Clin Oncol 2025;43(16_suppl):3144. ASCO 2025 Annual Meeting.",
    "performanceNotes": "Validation included 281 cancer-positive plasma samples across all stages and 201 healthy controls age 40+. Analytical LOD <0.1 ng cfDNA for 8/10 biomarkers. Uses incidence-adjusted sensitivity (more conservative than observed sensitivity).",
    "leadTimeNotes": "No lead time vs imaging data reported; designed for asymptomatic screening",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "reimbursement": "Self-Pay",
    "reimbursementNote": "No Medicare or commercial insurance coverage. Positioned as affordable/accessible alternative to NGS-based MCED tests.",
    "commercialPayers": [],
    "clinicalAvailability": "Commercially available in US via CLIA-certified lab in Tucson, AZ. Physician-ordered (not direct-to-consumer).",
    "availableRegions": ["US"],
    "tat": "5 days",
    "tatNotes": "Collection to report turnaround time (includes shipping and processing). Lab processing time is 2-3 days.",
    "sampleType": "Two 10-mL Streck cfDNA BCT tubes",
    "sampleVolume": "20 mL whole blood (two 10-mL tubes)",
    "cptCode": "UNKNOWN",
    "listPrice": 699,
    "screeningInterval": "Not specified",
    "clinicalTrials": "ASCO 2025 validation study (n=482); simulated 100,000-patient SEER-based screening cohort modeling",
    "totalParticipants": 482,
    "numPublications": 1,
    "numPublicationsPlus": false,
    "technologyDifferentiator": "PCR-based (not NGS) - enables faster TAT, lower cost, and global scalability vs sequencing-based MCED tests"
  },
  {
    "id": "ecd-12",
    "sampleCategory": "Blood/Plasma",
    "name": "ProVue Lung",
    "vendor": "PrognomiQ",
    "testScope": "Single-cancer (Lung)",
    "approach": "Blood-based proteomics",
    "method": "Proteomics-based analysis using proprietary multi-omics platform to detect unique molecular protein signatures of lung cancer; does not analyze ctDNA or methylation",
    "cancerTypes": [
      "Lung cancer (all types)"
    ],
    "targetPopulation": "High-risk adults aged 50+ with 20+ pack-year smoking history; consistent with USPSTF, ACS, and NCCN lung cancer screening guidelines",
    "indicationGroup": "Lung",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Single-cancer test; lung-specific",
    "sensitivity": 85.0,
    "sensitivityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html | https://prognomiq.com/provue/",
    "sensitivityNotes": "Overall sensitivity for all stages of lung cancer",
    "stageISensitivity": 81.0,
    "stageISensitivityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html",
    "stageISensitivityNotes": "Stage I sensitivity when treatment is most effective",
    "specificity": 55.0,
    "specificityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html | https://prognomiq.com/provue/",
    "specificityNotes": "Lower specificity results in higher false positive rate; designed as adjunct to LDCT screening",
    "npv": 99.8,
    "npvNotes": "NPV >99.8% indicates strong rule-out capability",
    "ppvDefinition": "Not publicly reported",
    "npvDefinition": "NPV for absence of lung cancer in high-risk screening population",
    "performanceCitations": "Unpublished data on file; manuscript under preparation. PrognomiQ website and press release Nov 2025.",
    "performanceNotes": "Validated in multiple prospective case-control studies. Binary result (ELEVATED or NOT ELEVATED). 85% sensitivity all-stage, 81% Stage I, 55% specificity, >99.8% NPV.",
    "leadTimeNotes": "Designed as adjunct to low-dose CT (LDCT); aims to improve screening compliance (currently <16% of eligible patients undergo annual LDCT)",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "fdaStatusNotes": "Laboratory is CLIA-certified and CAP-accredited. Not cleared or approved by FDA.",
    "reimbursement": "Self-Pay",
    "reimbursementNote": "No Medicare or commercial insurance coverage established. Available through Early Experience Program.",
    "commercialPayers": [],
    "clinicalAvailability": "Limited availability - Early Experience Program at select Pennsylvania health systems (Allegheny Health Network, Penn Highlands Healthcare Lung Innovations Network). Launched November 18, 2025.",
    "clinicalAvailabilityNotes": "Initial commercial launch through Early Experience Program to evaluate clinical workflow integration. Broader availability expected as program expands.",
    "tat": "Not publicly specified",
    "sampleType": "Blood (simple blood draw)",
    "sampleVolume": "Standard blood draw",
    "cptCode": "UNKNOWN",
    "listPrice": null,
    "listPriceNotes": "Pricing not publicly disclosed",
    "screeningInterval": "Not specified; designed to complement annual LDCT screening",
    "clinicalTrials": "Multiple prospective case-control validation studies (unpublished); Early Experience Program at Allegheny Health Network and Penn Highlands Healthcare",
    "totalParticipants": null,
    "totalParticipantsNotes": "Validation study size not publicly disclosed; manuscript under preparation",
    "numPublications": 0,
    "numPublicationsPlus": false,
    "numPublicationsNotes": "Manuscript under preparation; data presented on company website",
    "technologyDifferentiator": "Proteomics-based (not ctDNA/methylation) - first protein-based liquid biopsy for lung cancer detection; measures protein biomarkers rather than genetic or epigenetic signals; simple blood draw with no specialized collection tubes"
  },
  {
    "id": "ecd-13",
    "sampleCategory": "Blood/Plasma",
    "name": "Signal-C",
    "vendor": "Universal DX",
    "testScope": "Single-cancer (Colorectal)",
    "approach": "cfDNA methylation + fragmentation",
    "method": "Next-generation sequencing (NGS) analyzing cell-free DNA methylation patterns and fragmentation characteristics; multi-omics approach combining methylomics, fragmentomics, and machine learning algorithms to detect colorectal cancer and advanced adenomas from a single blood draw",
    "cancerTypes": [
      "Colorectal cancer (CRC)",
      "Advanced adenomas (pre-cancerous)"
    ],
    "targetPopulation": "Average-risk adults aged 45+ eligible for colorectal cancer screening per USPSTF guidelines",
    "indicationGroup": "CRC",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Single-cancer test; colorectal-specific",
    "sensitivity": 93,
    "sensitivityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://newsroom.questdiagnostics.com/2023-11-20-Universal-DX-Announces-Strategic-Collaboration-with-Quest-Diagnostics|https://www.universaldx.com/science",
    "sensitivityNotes": "93% sensitivity for CRC detection in 1,000-patient multi-cohort study presented at DDW 2023. Company website reports 92% sensitivity with 94% specificity in some materials - slight variations across presentations.",
    "stageISensitivity": 85,
    "stageISensitivityNotes": "Estimated from early-stage (I-II) combined sensitivity of 91%; Stage I likely ~85% based on typical stage distribution patterns. Exact Stage I data not separately reported.",
    "stageIISensitivity": 94,
    "stageIISensitivityNotes": "Estimated; early-stage (I-II) combined reported as 91%",
    "stageIIISensitivity": 97,
    "stageIIISensitivityNotes": "Later stages typically show higher sensitivity; estimated based on overall 93% and early-stage 91%",
    "stageIVSensitivity": 97,
    "stageIVSensitivityNotes": "Later stages typically show higher sensitivity; estimated based on overall 93% and early-stage 91%",
    "advancedAdenomaSensitivity": 54,
    "advancedAdenomaSensitivityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://newsroom.questdiagnostics.com/2023-11-20-Universal-DX-Announces-Strategic-Collaboration-with-Quest-Diagnostics",
    "advancedAdenomaSensitivityNotes": "54% sensitivity for advanced adenomas at 92% specificity. This pre-cancer detection capability is a key differentiator - may help prevent CRC, not just detect it.",
    "specificity": 92,
    "specificityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://www.universaldx.com/science",
    "specificityNotes": "92% specificity in DDW 2023 study. Some company materials report 94% specificity - may reflect different cohorts or thresholds.",
    "ppv": null,
    "ppvNotes": "Not publicly reported from validation studies",
    "npv": null,
    "npvNotes": "Not publicly reported from validation studies",
    "performanceCitations": "DDW 2023 presentation; ASCO GI 2023 presentation; https://www.universaldx.com/science",
    "performanceNotes": "Large 1,000-patient international multi-cohort case-control study with prospectively collected samples from US and Europe. Performance validated across multiple presentations at ASCO GI 2023 and DDW 2023.",
    "leadTimeNotes": "Blood-based alternative to colonoscopy and stool-based tests; aims to increase screening compliance among the ~40% of eligible adults not up-to-date on CRC screening",
    "fdaStatus": "Investigational – FDA pivotal trial ongoing",
    "fdaStatusCitations": "https://clinicaltrials.gov/study/NCT06059963 | https://www.businesswire.com/news/home/20240807274324/en/Universal-DX-Initiates-Clinical-Trial-for-FDA-Approval-of-Signal-C-Colorectal-Cancer-Screening-Blood-Test",
    "fdaStatusNotes": "FDA premarket approval (PMA) pivotal trial initiated January 2024. Targeting enrollment of 15,000+ patients across 100 investigator sites. Quest Diagnostics oncology center in Lewisville, TX serves as single testing site for trial.",
    "reimbursement": "Not yet established",
    "reimbursementNote": "Pending FDA approval; not currently available for clinical use in US",
    "commercialPayers": [],
    "clinicalAvailability": "Not yet commercially available – FDA pivotal trial in progress",
    "clinicalAvailabilityNotes": "Quest Diagnostics has exclusive US commercialization rights pending FDA approval (collaboration announced November 2023). Commercial launch expected following PMA approval.",
    "tat": "Not specified",
    "tatNotes": "Turnaround time not publicly disclosed; will be determined for commercial launch",
    "sampleType": "Blood (single draw)",
    "sampleVolume": "Not specified",
    "cptCode": "TBD",
    "cptCodesNotes": "CPT code to be established upon FDA approval and commercial launch",
    "listPrice": null,
    "listPriceNotes": "Pricing not yet established; pending FDA approval",
    "screeningInterval": "Not specified; likely aligned with standard CRC screening intervals (every 3 years typical for blood-based tests)",
    "clinicalTrials": "FDA pivotal trial (NCT06059963) - 15,000+ patient enrollment target across 100 sites; prior 1,000-patient validation study",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06059963",
    "totalParticipants": 1000,
    "totalParticipantsNotes": "1,000 patients in published validation study (DDW 2023); 15,000+ targeted for ongoing FDA pivotal trial",
    "numPublications": 3,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Multiple conference presentations at DDW 2023, ASCO GI 2023, AACR 2022; peer-reviewed publications in preparation",
    "technologyDifferentiator": "Multi-omics approach combining methylation + fragmentation analysis with machine learning. Company claims to have identified specific cfDNA sequence regions that capture cancer's earliest signals. Spain-based biotech (Universal DX) with US office in Cambridge, MA. Platform technology (Signal-X) being extended to other GI cancers including pancreatic, liver, and gastric."
  },
  // ============================================
  // IVD KITS - Self-Collection and Laboratory Kits
  // ============================================
  {
    "id": "ecd-kit-1",
    "sampleCategory": "Stool",
    "name": "Cologuard",
    "vendor": "Exact Sciences",
    "productType": "Self-Collection",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool DNA + FIT",
    "method": "Multi-target stool DNA test combining methylated BMP3/NDRG4, mutant KRAS, and fecal immunochemical test (FIT) for hemoglobin",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "Average-risk adults 45+ for CRC screening",
    "indicationsNotes": "FDA PMA-approved for CRC screening. At-home self-collection cancer screening test. Patient receives kit by mail, collects stool sample at home, ships to Exact Sciences lab.",
    "sensitivity": 92,
    "sensitivityNotes": "92% sensitivity for CRC; 42% for advanced adenomas in pivotal study",
    "stageISensitivity": 93,
    "stageIISensitivity": 94,
    "stageIIISensitivity": 93,
    "stageIVSensitivity": 92,
    "specificity": 87,
    "specificityNotes": "87% specificity; ~13% false positive rate",
    "ppv": 3.7,
    "ppvNotes": "PPV for CRC in average-risk screening population",
    "npv": 99.9,
    "fdaStatus": "FDA PMA-approved (2014)",
    "guidelinesNotes": "Included in USPSTF Grade A recommendation for CRC screening (stool DNA-FIT modality). NCCN, ACS, and ACG guidelines include mt-sDNA as screening option.",
    "reimbursement": "Medicare covered; most commercial payers",
    "reimbursementNote": "Covered by Medicare and most commercial insurers for average-risk CRC screening ages 45-85",
    "commercialPayers": ["UnitedHealthcare", "Aetna", "Cigna", "BCBS", "Humana"],
    "listPrice": 649,
    "listPriceNotes": "List price $649; typically covered by insurance with no out-of-pocket",
    "clinicalAvailability": "Self-collection kit shipped to patient home",
    "tat": "1-2 weeks",
    "screeningInterval": "Every 3 years",
    "totalParticipants": 10000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "At-home self-collection cancer screening - patient collects sample at home with no clinic visit required. Combines DNA biomarkers with FIT in single test. Included in USPSTF Grade A recommendation for CRC screening."
  },
  {
    "id": "ecd-kit-2",
    "sampleCategory": "Blood/Plasma",
    "name": "Epi proColon",
    "vendor": "Epigenomics",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Real-time PCR system",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA methylation",
    "method": "Detects methylated SEPT9 gene in plasma cfDNA via real-time PCR",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "Average-risk adults who decline colonoscopy or stool-based testing",
    "indicationsNotes": "FDA-approved blood-based CRC screening test. Intended for patients unwilling to undergo other screening methods.",
    "sensitivity": 68,
    "sensitivityNotes": "68% sensitivity for CRC (all stages); lower than stool-based tests",
    "stageISensitivity": 57,
    "stageIISensitivity": 72,
    "stageIIISensitivity": 85,
    "stageIVSensitivity": 78,
    "specificity": 80,
    "specificityNotes": "80% specificity in screening population",
    "fdaStatus": "FDA-approved (2016)",
    "reimbursement": "Coverage variable/limited",
    "reimbursementNote": "Medicare coverage has faced challenges; commercial coverage limited. Verify current coverage before ordering.",
    "commercialPayers": [],
    "listPrice": 192,
    "clinicalAvailability": "FDA-approved IVD kit for laboratory use",
    "tat": "3-5 days",
    "screeningInterval": "Annual",
    "totalParticipants": 8000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "First FDA-approved blood-based CRC screening test. Distributed IVD kit for labs with PCR capability. Positioned for patients who refuse colonoscopy and stool tests - 'better than no screening.'"
  }
];
